CHICAGO, Oct. 30, 2012 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO), which manufactures and markets the FC2 Female Condom, today announced that it will be presenting at the Singular Research Seventh Annual "Best of the Uncovereds" Conference on Thursday, November 1, 2012, in Los Angeles, California.
The Company's Chief Executive Officer, O.B. Parrish, and Chief Financial Officer, Donna Felch, are scheduled to present at 1:30 p.m. Pacific Time ( 4:30 p.m. Eastern Time). A live webcast of this presentation will be available on the Internet at http://www.singularresearch.com.
During the remainder of the day, management will meet with investors during a series of one-on-one breakout meetings. Interested parties should contact Bill Jones at Singular (267-987-2082) to schedule a meeting. The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles.About Singular ResearchSingular Research aims to be the most trusted supplier of independent single-source research on small-to-micro cap companies for small-to-medium-sized money managers. Singular will provide quarterly updates for 30 to 60 companies and make recommendations. Singular's goal is to provide initiation reports and quarterly updates for approximately 50 micro-to-small-cap companies. Singular's independent analysts have no financial interest in the stocks they cover. Analysts are compensated based on the accuracy of their research calls, not through trading commissions or potential deal flow. Singular's coverage list performance since inception in August 2004 is a positive 153.59% through December 2011, compared with a positive 13.88% for the S&P 500. For more information about Singular Research, visit http://www.singular-research.com. For more information about the conference, please contact: Robert Maltbie, CFA Singular Research818-222-6915 email@example.com About The Female Health Company The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and approximately 138 other countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in the U.S., the European Union, Canada, Australia, South Africa, Japan, The People's Republic of China, Spain, Mexico, Greece, Turkey and by the African Regional Intellectual Property Organization (ARIPO), which includes Botswana, The Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Somalia, Sudan, Swaziland, Uganda, United Republic of Tanzania, Zambia and Zimbabwe. FC2 patent applications are pending in various countries. The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies. "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from this currently anticipated. For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com. SOURCE The Female Health Company